IGM Biosciences, Inc.

IGM Biosciences, Inc. (IGMS) priced its initial public offering on Sep 18, 2019 at $16.00 per share, within its $15.00–$17.00 range, raising $175M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $462.3M. Jefferies was lead-left underwriter, joined by Stifel and Guggenheim. Wilson Sonsini advised the company and Cooley advised the underwriters.

IGM Biosciences, Inc. is a biotechnology company developing engineered IgM antibodies for cancer. Its lead candidate, IGM-2323, is a bispecific T cell engaging antibody targeting CD20 and CD3, planned for a Phase 1 trial in relapsed or refractory B cell non-Hodgkin's lymphoma.

Status

IPO

Ticker

IGMS

Exchange

Nasdaq Global Select

Priced

Sep 18, 2019

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$175M

Market cap at IPO price

$462.3M

First filed

Aug 19, 2019

Underwriters

Jefferies, Stifel and Guggenheim

Company counsel

Wilson Sonsini

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.